PT Tembaga Mulia Semanan Tbk (IDX:TBMS)

Regulus Therapeutics Revenue

PT Tembaga Mulia Semanan Tbk had revenue of $216.49M USD in the quarter ending June 30, 2025, with 9.61% growth. This brings the company's revenue in the last twelve months to $904.10M, up 19.51% year-over-year. In the year 2024, PT Tembaga Mulia Semanan Tbk had annual revenue of $863.77M with 16.17% growth.

• Revenue (ttm): $904.10M
• Revenue Growth: +19.51%
• P/S Ratio: 0.05
• Revenue / Employee: $3.42M
• Employees: 264
• Market Cap: 756.72B

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	863.77M	120.22M	16.17%
Dec 31, 2023	743.55M	20.92M	2.89%
Dec 31, 2022	722.63M	1.90M	0.26%
Dec 31, 2021	720.73M	269.68M	59.79%
Dec 31, 2020	451.05M	-132.77M	-22.74%